rusfertide (PTG-300) - Protagonist Therap, Takeda
Rusfertide: Launch in US for polycythemia vera in 2026 (Protagonist Therapeutics) - Aug 15, 2024 - Corporate Presentation 
Launch US Hematological Malignancies • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera
https://irp.cdn-website.com/8e9b9820/files/uploaded/2024_PTGX_CorpDeck_06Aug2024_FINAL.pdf
 
Aug 15, 2024
 
 
8ede1a20-fb4d-43ba-bcb6-82f9157eb9ad.png